New treatments for copd
- 1 June 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 1 (6) , 437-446
- https://doi.org/10.1038/nrd820
Abstract
COPD is one of the most common diseases in the world, and there is a global increase in prevalence, but there are no drugs available at present that halt the relentless progression of this disease. However, a better understanding of the cellular and molecular mechanisms that are involved in the underlying inflammatory and destructive processes has revealed several new targets for which drugs are now in development, and the prospects for finding new treatments are good.Keywords
This publication has 86 references indexed in Scilit:
- Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophagesThe FASEB Journal, 2001
- p38 MAP kinase and MKK‐1 co‐operate in the generation of GM‐CSF from LPS‐stimulated human monocytes by an NF‐κB‐independent mechanismBritish Journal of Pharmacology, 2000
- Regular review: Effectiveness of interventions to help people stop smoking: findings from the Cochrane LibraryBMJ, 2000
- InfliximabDrugs, 2000
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000
- INHIBITION OF NITRIC OXIDE SYNTHASE AS A POTENTIAL THERAPEUTIC TARGETAnnual Review of Pharmacology and Toxicology, 1999
- Tiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung diseaseLife Sciences, 1999
- EtanerceptDrugs, 1999
- ONO-5046, a novel inhibitor of human neutrophil elastaseBiochemical and Biophysical Research Communications, 1991
- The natural history of chronic airflow obstruction.BMJ, 1977